Forvis Wealth Advisors, LLC Gilead Sciences, Inc. Transaction History

Forvis Wealth Advisors, LLC

$3.96 Billion
Q2 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$71.58 - $87.29 $28,345 - $34,566	-396 Reduced 10.56%	3,355 $245,000
Q4 2023 Jan 11, 2024	BUY	$73.27 - $83.09 $21,687 - $24,594	296 Added 8.57%	3,751 $303,000
Q3 2023 Oct 25, 2023	SELL	$73.94 - $80.67 $50,574 - $55,178	-684 Reduced 16.53%	3,455 $258,000
Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $73,653 - $84,012	969 Added 30.57%	4,139 $318,000
Q1 2023 Apr 26, 2023	BUY	$77.31 - $88.08 $231 - $264	3 Added 0.09%	3,170 $263,000
Q4 2022 Feb 02, 2023	SELL	$62.32 - $89.47 $31,596 - $45,361	-507 Reduced 13.8%	3,167 $271,000
Q3 2022 Oct 13, 2022	SELL	$59.54 - $68.01 $297 - $340	-5 Reduced 0.14%	3,674 $227,000
Q2 2022 Jul 22, 2022	SELL	$57.72 - $65.01 $7,676 - $8,646	-133 Reduced 3.49%	3,679 $227,000
Q1 2022 May 10, 2022	BUY	$57.92 - $72.58 $61,626 - $77,225	1,064 Added 38.72%	3,812 $227,000
Q4 2021 Jan 14, 2022	BUY	$64.88 - $73.64 $178,290 - $202,362	2,748 New	2,748 $200,000
Q3 2021 Oct 14, 2021	SELL	$67.69 - $73.03 $206,589 - $222,887	-3,052 Closed	0 $0
Q2 2021 Jul 14, 2021	SELL	$63.47 - $69.35 $124,337 - $135,856	-1,959 Reduced 39.09%	3,052 $210,000
Q1 2021 Apr 23, 2021	SELL	$60.0 - $68.46 $252,780 - $288,421	-4,213 Reduced 45.67%	5,011 $324,000
Q4 2020 Jan 22, 2021	SELL	$56.65 - $64.55 $316,900 - $361,092	-5,594 Reduced 37.75%	9,224 $537,000
Q3 2020 Nov 05, 2020	SELL	$62.1 - $78.08 $289,944 - $364,555	-4,669 Reduced 23.96%	14,818 $936,000
Q2 2020 Jul 15, 2020	SELL	$72.34 - $84.0 $117,986 - $137,004	-1,631 Reduced 7.72%	19,487 $1.5 Million
Q1 2020 Apr 10, 2020	SELL	$62.63 - $80.22 $154,320 - $197,662	-2,464 Reduced 10.45%	21,118 $1.58 Million
Q4 2019 Jan 13, 2020	SELL	$61.62 - $67.78 $1.28 Million - $1.41 Million	-20,828 Reduced 46.9%	23,582 $1.53 Million
Q3 2019 Oct 29, 2019	BUY	$62.51 - $69.0 $395,250 - $436,287	6,323 Added 16.6%	44,410 $2.82 Million
Q2 2019 Jul 10, 2019	BUY	$61.87 - $69.38 $3,650 - $4,093	59 Added 0.16%	38,087 $2.57 Million
Q1 2019 Apr 10, 2019	BUY	$62.53 - $70.05 $1.32 Million - $1.48 Million	21,183 Added 125.75%	38,028 $2.47 Million
Q4 2018 Jan 15, 2019	SELL	$60.54 - $79.0 $944,121 - $1.23 Million	-15,595 Reduced 48.07%	16,845 $1.05 Million
Q3 2018 Oct 09, 2018	BUY	$71.28 - $78.92 $267,228 - $295,871	3,749 Added 13.07%	32,440 $2.51 Million
Q2 2018 Jul 13, 2018	BUY	$64.88 - $75.68 $222,797 - $259,885	3,434 Added 13.6%	28,691 $2.03 Million
Q1 2018 May 25, 2018	SELL	$72.84 - $88.8 $36,711 - $44,755	-504 Reduced 1.96%	25,257 $1.9 Million
Q1 2018 Apr 20, 2018	BUY	$72.84 - $88.8 $294,055 - $358,485	4,037 Added 18.58%	25,761 $1.95 Million
Q4 2017 Jan 18, 2018	BUY	$71.15 - $83.52 $948,144 - $1.11 Million	13,326 Added 158.68%	21,724 $1.56 Million
Q3 2017 Oct 13, 2017	BUY	$72.11 - $85.47 $605,579 - $717,777	8,398	8,398 $680,000

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

Black Rock Inc. New York, NY

121M
Shares

$10.6 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.15% of portfolio
Capital World Investors Los Angeles, CA

76.2M
Shares

$6.72 Billion
0.88% of portfolio
Capital Research Global Investors Los Angeles, CA

60.4M
Shares

$5.32 Billion
0.94% of portfolio
State Street Corp Boston, MA

59.3M
Shares

$5.23 Billion
0.18% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Forvis Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Forvis Wealth Advisors, LLC with notifications on news.

Account